Tenax Therapeutics (TENX) Competitors $5.95 +0.05 (+0.85%) Closing price 07/15/2025 03:57 PM EasternExtended Trading$6.04 +0.09 (+1.58%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. CRBP, OKYO, CHRS, WHWK, VIRI, MGNX, OCX, ZNTL, FBRX, and BYSIShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Corbus Pharmaceuticals (CRBP), OKYO Pharma (OKYO), Coherus Oncology (CHRS), Whitehawk Therapeutics (WHWK), Virios Therapeutics (VIRI), MacroGenics (MGNX), OncoCyte (OCX), Zentalis Pharmaceuticals (ZNTL), Forte Biosciences (FBRX), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Its Competitors Corbus Pharmaceuticals OKYO Pharma Coherus Oncology Whitehawk Therapeutics Virios Therapeutics MacroGenics OncoCyte Zentalis Pharmaceuticals Forte Biosciences BeyondSpring Corbus Pharmaceuticals (NASDAQ:CRBP) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk. Is CRBP or TENX more profitable? Tenax Therapeutics' return on equity of -31.51% beat Corbus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corbus PharmaceuticalsN/A -36.87% -32.87% Tenax Therapeutics N/A -31.51%-30.35% Do insiders and institutionals hold more shares of CRBP or TENX? 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 4.0% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, CRBP or TENX? Corbus Pharmaceuticals has a beta of 3.05, indicating that its share price is 205% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Do analysts rate CRBP or TENX? Corbus Pharmaceuticals currently has a consensus target price of $50.88, suggesting a potential upside of 531.20%. Tenax Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 194.12%. Given Corbus Pharmaceuticals' higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has higher valuation & earnings, CRBP or TENX? Tenax Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorbus PharmaceuticalsN/AN/A-$40.21M-$4.22-1.91Tenax TherapeuticsN/AN/A-$17.60M-$2.48-2.40 Does the media refer more to CRBP or TENX? In the previous week, Corbus Pharmaceuticals had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 3 mentions for Corbus Pharmaceuticals and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.89 beat Corbus Pharmaceuticals' score of 0.85 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Corbus Pharmaceuticals Positive Tenax Therapeutics Very Positive SummaryCorbus Pharmaceuticals beats Tenax Therapeutics on 7 of the 13 factors compared between the two stocks. Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.48M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-2.4020.2228.5419.58Price / SalesN/A298.23430.1194.56Price / CashN/A43.1536.0257.93Price / Book0.227.568.145.54Net Income-$17.60M-$55.11M$3.24B$257.73M7 Day Performance0.59%3.81%0.17%-0.08%1 Month Performance-2.62%11.60%5.95%8.09%1 Year Performance73.47%-2.11%26.22%13.02% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics1.6569 of 5 stars$5.95+0.8%$17.50+194.1%+77.1%$24.48MN/A-2.409Positive NewsCRBPCorbus Pharmaceuticals4.2975 of 5 stars$7.30-5.3%$50.88+596.9%-86.4%$94.35MN/A-1.7340News CoverageOKYOOKYO Pharma3.3213 of 5 stars$2.82+1.4%$7.00+148.2%+73.0%$94.07MN/A0.007Gap UpCHRSCoherus Oncology3.7534 of 5 stars$0.75-7.9%$4.68+527.6%-48.5%$93.91M$266.96M-0.66330WHWKWhitehawk TherapeuticsN/A$1.98-0.5%N/AN/A$93.75M$25.98M0.0040VIRIVirios TherapeuticsN/A$4.80-0.6%$5.00+4.2%+1,981.1%$92.44MN/A-17.785MGNXMacroGenics4.3133 of 5 stars$1.36-6.8%$5.71+320.2%-69.2%$92.11M$149.96M-1.53430OCXOncoCyte1.2384 of 5 stars$3.18+16.3%$6.06+90.9%-5.5%$90.80M$3.84M-0.90120ZNTLZentalis Pharmaceuticals2.4733 of 5 stars$1.19-5.6%$8.37+603.1%-66.3%$90.66M$67.43M-0.38160News CoveragePositive NewsFBRXForte Biosciences3.4935 of 5 stars$12.65-7.4%$61.00+382.2%+42,163.0%$89.93MN/A-0.785Positive NewsBYSIBeyondSpringN/A$2.27+1.8%N/A+2.7%$89.90M$1.75M0.0080Gap Up Related Companies and Tools Related Companies Corbus Pharmaceuticals Alternatives OKYO Pharma Alternatives Coherus Oncology Alternatives Whitehawk Therapeutics Alternatives Virios Therapeutics Alternatives MacroGenics Alternatives OncoCyte Alternatives Zentalis Pharmaceuticals Alternatives Forte Biosciences Alternatives BeyondSpring Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
